TABLE 4.
Cause of death relative to the CCI risk score
| CCI 2 | CCI 3 | CCI ≥ 4 | P‐value | |
|---|---|---|---|---|
| Number of patients (%) | Number of patients (%) | Number of patients (%) | ||
| All patients (n = 452) | 353 (78.1) | 72 (15.9) | 27 (6.0) | |
| Entire cohort | ||||
| Total number of death (all causes) | 13 (3.7) | 6 (8.3) | 5 (18.5) | <.01 |
| Cause of death | ||||
| CML‐related death | 4 (1.1) | 2 (2.8) | 0 (0.0) | .45 |
| CML‐unrelated death | 9 (2.5) | 4 (5.6) | 5 (18.5) | <.001 |
| Cancer | 4 (1.1) | 0 (0.0) | 3 (11.1) | <.001 |
| VAE | 0 (0.0) | 2 (2.8) | 1 (3.7) | <.01 |
| Infection | 3 (0.8) | 0 (0.0) | 1 (3.7) | .21 |
| Others | 2 (0.6) | 2 (2.8) | 0 (0.0) | .17 |
| Imatinib cohort | ||||
| Number of patients (n = 139) | 96 (69.1) | 34 (24.5) | 9 (6.4) | |
| Total number of death (all causes) | 9 (9.4) | 2 (5.9) | 4 (44.4) | <.01 |
| Cause of death | ||||
| CML‐related death | 4 (4.2) | 1 (2.9) | 0 (0.0) | .79 |
| CML‐unrelated death | 5 (5.2) | 1 (2.9) | 4 (44.4) | <.001 |
| Cancer | 3 (3.1) | 0 (0.0) | 2 (22.2) | <.01 |
| VAE | 0 (0.0) | 0 (0.0) | 1 (11.1) | <.01 |
| Infection | 1 (1.0) | 0 (0.0) | 1 (11.1) | .04 |
| Others | 1 (1.0) | 1 (2.9) | 0 (0.0) | .68 |
| 2GTKI cohort | ||||
| Number of patients (n = 313) | 257 (82.1) | 38 (12.1) | 18 (5.8) | |
| Total number of death (all cause) | 4 (1.6) | 4 (10.5) | 1 (5.6) | <.01 |
| Cause of death | ||||
| CML‐related death | 0 (0.0) | 1 (2.6) | 0 (0.0) | .03 |
| CML‐unrelated death | 4 (1.6) | 3 (7.9) | 1 (5.6) | .05 |
| Cancer | 1 (0.4) | 0 (0.0) | 1 (5.6) | .03 |
| VAE | 0 (0.0) | 2 (5.3) | 0 (0.0) | <.01 |
| Infection | 2 (0.8) | 0 (0.0) | 0 (0.0) | .8 |
| Others | 2 (0.6) | 1 (2.6) | 0 (0.0) | .25 |
Abbreviations: 2GTKI, second‐generation tyrosine kinase inhibitor; CCI, Charlson Comorbidity Index; CML, chronic myeloid leukemia; VAE, vascular adverse event.